Journal article
Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments
Journal of pharmacy & pharmaceutical sciences, Vol.29, 15714
03/01/2026
DOI: 10.3389/jpps.2026.15714
PMID: 41859285
Abstract
Asthma and allergies affect millions of people globally. Avoiding triggers and allergens is a basic management technique for all asthma subtypes (>80% of asthma patients also suffer from allergies), and pharmacological treatment is the cornerstone for acute exacerbations and ongoing maintenance. Typical treatment options for asthma include inhaled, oral, or injectable dosage forms. However, transdermal drug delivery has great potential to provide an alternative route of administration of necessary asthma and allergy therapies that have traditionally been given in other dosage forms. In Part 1 of this two-part series, we discussed the work done towards incorporating short- and long-acting β2-agonists into transdermal drug delivery systems. Here in part 2, we describe the current literature for transdermal applications of leukotriene antagonists, theophylline, and other adjunct medications that do not fall into one specific drug class. A brief overview of biologics, particularly monoclonal antibodies, and the role in asthma is also included, including some context of transdermal mAb delivery for disease states beyond asthma. Because of the relatedness of asthma and allergies, transdermal applications for allergen immunotherapy is also discussed.
Details
- Title: Subtitle
- Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments
- Creators
- Joseph Correa - Io Therapeutics (United States)Nicole K. Brogden - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of pharmacy & pharmaceutical sciences, Vol.29, 15714
- DOI
- 10.3389/jpps.2026.15714
- PMID
- 41859285
- NLM abbreviation
- J Pharm Pharm Sci
- ISSN
- 1482-1826
- eISSN
- 1482-1826
- Publisher
- Frontiers Media S.A
- Grant note
- National Institutes of Health: 1R35GM149337 Iowa Biotech Training Program - T32 grantNational Institute of General Medical Sciences Predoctoral Institutional Research Training Grant: NIGMS T32 GM152268 Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Institutes of Health awards 1R35GM149337. Funding to support Joseph Correa's efforts was partially provided from the Iowa Biotech Training Program as funded by a T32 grant awarded by the National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant (NIGMS T32 GM152268) and administered by the Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa.
- Language
- English
- Date published
- 03/01/2026
- Academic Unit
- Dermatology; Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9985143134302771
Metrics
1 Record Views